Table 3.
Proposed utilization of urinary furosemide and urinary sodium with decreased urine response to FST.
| Urinary furosemide (FEM2) |
||
|---|---|---|
| FEM high | FEM low | |
| Urine Sodium | ||
| High Sodium | Physiology: Consistent preserved proximal tubular function and distal injury preventing sodium reabsorption Syndrome: This profile would be consistent with kidney injury that has a TAL or distal injury profile |
Physiology: Consistent with tubular injury resulting inability to reabsorb sodium or to secrete furosemide Syndrome: This profile would be consistent with acute tubular injury and acute tubular necrosis |
| Low Sodium | Physiology: Demonstrates sufficient oxygen transport to the kidney to enable effective bi-directional proximal tubular function as evidenced by sodium reabsorption and furosemide secretion Syndromes that would show this pathophysiology: decreased effective circulating volume, congestive heart failure, cardiorenal syndrome, central venous congestion |
Physiology: Demonstrates sufficient oxygen transport to the kidney to maintain sodium reabsorption but inability to secrete furosemide. Syndrome: This physiology would be consistent with a profound hypo-albuminemia state and may be indicative of the threshold wherein albumin replacement therapy is indicated |